ADVANTAGEOUS ANTI-HCV COMBINATION THERAPY
A synergistic pharmaceutical combination of Compound 1 or a pharmaceutically acceptable salt thereof (e.g., Compound 1-A) and Compound 2 or a pharmaceutically acceptable salt thereof, as well as its uses to treat hepatitis C or a condition related to hepatitis C, as well as methods for the manufacture of the pharmaceutical combination:
1 . A method of treating HCV in a human in need thereof, comprising administering an effective amount of Compound 1, or a pharmaceutically acceptable salt thereof,
optionally in a pharmaceutically acceptable carrier in combination with an effective amount of Compound 2, or a pharmaceutically acceptable salt thereof.
optionally in a pharmaceutically acceptable carrier.
2 . The method of claim 1 , wherein Compound 1 is Compound 1-A
3 . The method of claim 1 , wherein Compound 1 or a pharmaceutically acceptable salt thereof and Compound 2 or a pharmaceutically acceptable salt thereof are in the same pharmaceutically acceptable carrier.
4 . The method of claim 3 , wherein Compound 1 or a pharmaceutically acceptable salt thereof is Compound 1-A.
5 . The method of claim 1 , wherein Compound 1 or a pharmaceutically acceptable salt thereof and Compound 2 or a pharmaceutically acceptable salt thereof are in different pharmaceutically acceptable carriers.
6 . The method of claim 5 , wherein Compound 1 or a pharmaceutically acceptable salt thereof is Compound 1-A.
7 . The method of claim 1 , wherein the combination is administered orally.
8 . The method of claim 1 , wherein the combination is administered parenterally.
9 . The method of claim 1 , wherein from about 100 mg to about 800 mg of Compound 1, or an equivalent amount of a pharmaceutically acceptable salt thereof, is administered.
10 . The method of claim 9 , wherein at least about 550 mg of Compound 1, or an equivalent amount of a pharmaceutically acceptable salt thereof, is administered.
11 . The method of claim 10 , wherein from about 90 to about 360 mg of Compound 2 or a pharmaceutically acceptable salt thereof is administered.
12 . The method of claim 11 , wherein at least about 180 mg of Compound 2 or a pharmaceutically acceptable salt is administered.
13 . The method of claim 1 , wherein the combination is administered once per day.
14 . The method of claim 1 , wherein the combination is administered twice per day.
15 . The method of claim 12 , wherein the combination is administered once per day.
16 . The method of claim 12 , wherein the combination is administered twice per day.
17 . The method of claim 1 , wherein the combination is administered for up to 12 weeks.
18 . The method of claim 1 , wherein the combination is administered for up to 8 weeks.
19 . The method of claim 1 , wherein the combination is administered for up to 6 weeks.
20 . The method of claim 1 , wherein the host is a human.
21 . The method of claim 20 , wherein the HCV infection is genotype 1.
22 . The method of claim 20 , wherein the HCV infection is genotype 2.
23 . The method of claim 20 , wherein the HCV infection is genotype 3.
24 . The method of claim 20 , wherein the HCV infection is genotype 4.
25 . The method of claim 20 , wherein the HCV infection is genotype 5.
26 . The method of claim 20 , wherein the HCV infection is genotype 6.
27 . The method of claim 20 , wherein the HCV is a resistance associated mutant.